Evidence Table E47. Binge eating disorder behavioral and drug treatment – part 11

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Agras, 199449 | Drop-out during tx, N (%):G1: 8 (23%)G2: 6 (17%)G3: 10 (27%)(P = NS)Drop out during 3-mth FU, N:G1: 3G2: 5G3: 6 | G1: "24% of participants in this group discontinued desipramine before the posttreatment assessment because of side effects." | NR | NR | NR | NR |
| Brambilla, 200950 | 5 dropped out, 4 at the beginning due to "lack of motivation" and 1 during treatment for unspecified reasons.G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR | G1: NRG2: NRG3: NR |
| Claudino, 200751 | G1: 7G2: 10p = 0.37 | G1: 1G2: 0 | NR | None | Overall: G1: 127G2: 98Mean Between-group difference (95% CI): NRp = NR | Overall: G1: 2G2: 7Mean Between-group difference (95% CI): NRp = NS |

Evidence Table E47. Binge eating disorder behavioral and drug treatment – part 11 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Devlin, 200752Devlin, 200553 | Post-treatment dropoutOverall: 42 (36%)G1: NRG2: NRG3: NRG4: NRG1+G2: N = 32%G3+G4: N = 40%G1+G3: N = 28%G2+G4: N = 45%G1+G3 v. G2+G4, p=NSMean Between-group difference (95% CI): NRp = NRAssessed at 6 months: N=88Assessed at 12 months: N=88Assessed at 18 months: N=87Assessed at 24 months: N=87Number of follow-up assessments completed did not differ by treatment | G1: NRG2: NRG3: NRG4: NRMean Between-group difference (95% CI): NRp = NR1 taking fluoxetine, but not clear if G1 or G3 | G1: NRG2: NRG3: NRG4: NRMean Between-group difference (95% CI): NRp = NROverall: 15 dropped because treatment not helping or no longer interested; 2 assigned to placebo due to unimproved depression symptoms but not clear if G2 or G4 | G1: NRG2: NRG3: NRG4: NRMean Between-group difference (95% CI): NRp = NR | G1: NRG2: NRG3: NRG4: NRMean Between-group difference (95% CI): NRp = NR | G1: NRG2: NRG3: NRG4: NRMean Between-group difference (95% CI): NRp = NR |

Evidence Table 47. Binge eating disorder behavioral and drug treatment – part 11 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Golay, 200554 | G1: 5 (11%)G2: 13 (29%)Mean Between-group difference (95% CI): NRp = NR | Overall: G1: 0G2: 4Mean Between-group difference (95% CI): NRp = NR | Overall: G1: 0G2: 2Mean Between-group difference (95% CI): NRp = NR | NR | NR | NR |
| Grilo, 200555 | G1: 6G2: 5Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: 2G2: 0Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: 1G2: 0Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR"The overall frequency of reported side effects (at any time during the study) was only slightly higher in G1 than G2, although reports of certain GI events known to be due to orlistat's mode of action were higher for G1. In almost all cases, these events occurred early in treatment, tended to be mild, and were transient." | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR |

Evidence Table 47. Binge eating disorder behavioral and drug treatment – part 11 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Grilo, 201356 | Overall: N=11G1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR |
| Grilo, 200557Grilo, 201258Grilo, 201259Grilo, 200660 | Post-treatmentOverall: 22 (20%)G1: 22%G2: 15%G3: 23%G4: 21%Did not complete 6 month followupG1: 41%G3: 35%G4: 25%Did not complete 12 month followupG1: 37%G3: 27%G4: 21% | NR | NR | NR | NR | NR |
| Laederach-Hofmann, 199961 | Overall: 2G1: 1G2: 1 | G1: 1G2: 1 | NR | NR | G1: 1G1: 1 | NR |

Evidence Table 47. Binge eating disorder behavioral and drug treatment – part 11 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Lanzarone, 201462 | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR | G1: NRG2: NRG3: NRMean Between-group difference (95% CI): NR p = NR |
| Molinari, 200563 | Overall: 5 (8%)G1: 2G2: 1G3: 2Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRMean Between-group difference (95% CI): NRp = NR |

Evidence Table 47. Binge eating disorder behavioral and drug treatment – part 11 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Harms Overall Discontinuation From Study | Discontinuation Due to AEs | Discontinuation Due to Lack of Efficacy | Serious AEs (Define in Addition to Reporting Rates) | Any AE | Diarrhea |
| Ricca, 200164 | Overall: 25G1: 3G2: 6G3: 5G4: 5G5: 6Mean Between-group difference (95% CI): NRNumber of dropouts in the 5 groups were not significantly different. Patients who dropped out were not significantly different from those who completed treatment for age, BMI, psychiatric comorbidity, and baseline scores of psychometric tests.p = NR, NS | Overall: NRG1: 0G2: 3G3: 3G4: 2G5: 4Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRG4: NRG5: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRG3: NRG4: NRG5: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: 0G2: 6G3: 6G4: 7G5: 0Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: 0G2: 0G3: 1G4: 0G5: 0Mean Between-group difference (95% CI): NRp = NR |
| Ricca, 200965 | G1: 8 (33%)G2: 14 (50%)Mean Between-group difference (95% CI): NRp = NR, NS | Overall: NRG1: NRG2: 6Mean Between-group difference (95% CI): NRp = NR | Overall: 1G1: 0G2: 1Mean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR | Overall: NRG1: NRG2: NRMean Between-group difference (95% CI): NRp = NR |